2026WCLC | Favorable Phase 1b Data on RC148 (ABBV-1480) as 1L Therapy for Squamous and Non-Squamous NSCLC Presented, with Phase III Protocol Unveiled

2026-09-15

The 2026 World Conference on Lung Cancer (WCLC 2026) was held in Seoul, South Korea, on September 12 to 15, 2026 (GMT +9). As the world's largest academic conference on lung cancer research, WCLC brought together experts and researchers from over

The Journal of Clinical Oncology (JCO) Publishes Full Results of Disitamab Vedotin in a "Triple-Drug Combination" (RCTS) Regimen for First-Line Gastric Cancer Therapy

2026-06-28

On June 27, the world-renowned oncology journal Journal of Clinical Oncology (JCO) published the full research paper from a Phase II RCTS trial online. The study evaluated the combination of Disitamab Vedotin, Tislelizumab, and S-1 as a first-line th

First Patient In Achieved in RemeGen’s Phase II/III Clinical Study of RC148 in Combination with Chemotherapy as First-Line Therapy for Unresectable or Metastatic Colorectal Cancer

2026-06-15

OnJun 15th, RemeGen (688331.SH/09995.HK) announced that the first patient has been dosed in its Phase II/III clinical study of RC148 (RC148-C303), a novel bispecific antibody independently developed by RemeGen, in combination with chemotherapy as first-li

Remegen's Telitacicept Two Indications Approved on the Same Day, Patients with Sjögren's Syndrome (Dry Disease) and IgA Nephropathy Welcome the World's First Dual-Target Biologic Drug

2026-06-08

On June 8, Remegen (688331.SH/09995.HK) announced that its self-developed global first-in-class BLyS/APRIL dual-target fusion protein innovative drug Telitacicept (RC18) has received approval from the China National Medical Products Administration (NMPA)

2026 EAU | Original Research Findings on Disitamab Vedotin Unveiled: Showcasing Breakthroughs in Urothelial Carcinoma Care

2026-04-17

The Annual European Association of Urology Congress 2026 (EAU Congress 2026), one of the world’s premier urological events, was held in London, the United Kingdom, from March 13 to 16, 2026 (UTC+0). At the congress, results of multiple researches

2026 ASCO-GU | RC48-C017 study update: Disitamab vedotin plus immunotherapy as neoadjuvant treatment delivers lasting survival gains in bladder cancer.

2026-02-28

On February 27 local time, at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) held in San Francisco, USA, the latest efficacy and safety data from the extended follow-up of the phase II clinical study (RC48-C017) o